BRPI0513888A - composição medicinal, métodos para a profilaxia ou tratamento de uma doença autoimune, e para preparação da composição medicinal, uso de uma composição medicinal, procedimento de administração, e, agente terapêutico - Google Patents

composição medicinal, métodos para a profilaxia ou tratamento de uma doença autoimune, e para preparação da composição medicinal, uso de uma composição medicinal, procedimento de administração, e, agente terapêutico

Info

Publication number
BRPI0513888A
BRPI0513888A BRPI0513888-4A BRPI0513888A BRPI0513888A BR PI0513888 A BRPI0513888 A BR PI0513888A BR PI0513888 A BRPI0513888 A BR PI0513888A BR PI0513888 A BRPI0513888 A BR PI0513888A
Authority
BR
Brazil
Prior art keywords
medicinal composition
therapeutic agent
prophylaxis
preparation
treatment
Prior art date
Application number
BRPI0513888-4A
Other languages
English (en)
Inventor
Takahide Nishi
Takaichi Shimozato
Takashi Kagari
Hiromi Doi
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co filed Critical Sankyo Co
Publication of BRPI0513888A publication Critical patent/BRPI0513888A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/335—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)

Abstract

COMPOSIçãO MEDICINAL, MéTODOS PARA A PROFILAXIA OU TRATAMENTO DE UMA DOENçA AUTOIMUNE, E PARA PREPARAçãO DA COMPOSIçãO MEDICINAL, USO DE UMA COMPOSIçãO MEDICINAL, PROCEDIMENTO DE ADMINISTRAçãO, E, AGENTE TERAPêUTICO Uma composição medicinal útil como um agente de prevenção ou terapêutico paras doenças relacionadas com a imunização. A composição medicinal compreende pelo menos um membro selecionado do grupo que consiste de inibidores da HMG-CoA redutase e pelo menos um membro selecionado do grupo que consiste de um derivado de aminoálcool representado pela seguinte fórmula geral (I), um sal farmacologicamente aceitável do derivado e um éster farmacologicamente aceitável do derivado. ¢Na fórmula, R¬ 1¬ e R¬ 2¬ são os mesmos ou diferentes e cada um representa um hidrogênio, etc.; R¬ 3¬ representa alquila inferior, etc.; R¬ 4¬ representa hidrogênio,etc.; R¬ 5¬ representa hidrogênio, halogênio, fenila, etc.; X representa vinileno (CH=CH), nitrogênio metilado, etc.; Y representa uma ligação simples, oxigênio, enxofre ou carbonila; Z representa alquileno C~ 1~-C~ 8~, etc.; n é 2 ou 3 e os substituintes a representam alquila inferior, alcóxi inferior, fenila, etc.!
BRPI0513888-4A 2004-07-29 2005-07-28 composição medicinal, métodos para a profilaxia ou tratamento de uma doença autoimune, e para preparação da composição medicinal, uso de uma composição medicinal, procedimento de administração, e, agente terapêutico BRPI0513888A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004222420 2004-07-29
PCT/JP2005/013843 WO2006011554A1 (ja) 2004-07-29 2005-07-28 免疫抑制剤としての医薬組成物

Publications (1)

Publication Number Publication Date
BRPI0513888A true BRPI0513888A (pt) 2008-05-20

Family

ID=35786302

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0513888-4A BRPI0513888A (pt) 2004-07-29 2005-07-28 composição medicinal, métodos para a profilaxia ou tratamento de uma doença autoimune, e para preparação da composição medicinal, uso de uma composição medicinal, procedimento de administração, e, agente terapêutico

Country Status (10)

Country Link
US (1) US20070149597A1 (pt)
EP (1) EP1782804B1 (pt)
KR (1) KR20070042986A (pt)
CN (1) CN101027048A (pt)
AT (1) ATE538780T1 (pt)
BR (1) BRPI0513888A (pt)
CA (1) CA2575518A1 (pt)
ES (1) ES2377975T3 (pt)
TW (1) TW200611687A (pt)
WO (1) WO2006011554A1 (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2330839C2 (ru) * 2002-01-11 2008-08-10 Санкио Компани, Лимитед Производные аминоспиртов или производные фосфорных кислот и фармацевтические композиции, содержащие указанные производные
TWI355934B (en) 2004-02-24 2012-01-11 Sankyo Co Pharmaceutical composition for treatment or prophy
ATE502630T1 (de) 2004-07-16 2011-04-15 Kyorin Seiyaku Kk Verfahren zur effektiven anwendung eines medikaments und verfahren zur prävention von nebenwirkungen
AU2005292984B2 (en) 2004-10-12 2011-01-20 Kyorin Pharmaceutical Co., Ltd. Process for producing 2-amino-2-[2-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]ethyl]-1,3-propanediol hydrochloride or hydrate thereof and intermediate for the same
TWI418350B (zh) * 2005-06-24 2013-12-11 Sankyo Co 含有ｐｐａｒ調節劑之醫藥組成物的用途
RU2421214C2 (ru) * 2005-10-07 2011-06-20 Киорин Фармасьютикал Ко., Лтд. Терапевтическое средство для лечения гепатита и способ лечения гепатита
PT1961734E (pt) * 2005-12-15 2011-10-06 Mitsubishi Tanabe Pharma Corp Composto de amina e sua utilização para fins médicos
TWI389683B (zh) * 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
US8232319B2 (en) * 2006-08-08 2012-07-31 Kyorin Pharmaceutical Co., Ltd. Amino phosphate derivative and S1P receptor modulator having same as an active ingredient
JP5140593B2 (ja) * 2006-08-08 2013-02-06 杏林製薬株式会社 アミノアルコール誘導体及びそれらを有効成分とする免疫抑制剤
US20090176744A1 (en) * 2007-11-02 2009-07-09 Concert Pharmaceuticals, Inc. Deuterated fingolimod
TW200946105A (en) * 2008-02-07 2009-11-16 Kyorin Seiyaku Kk Therapeutic agent or preventive agent for inflammatory bowel disease containing amino alcohol derivative as active ingredient
HRP20161133T1 (hr) 2008-07-23 2016-12-02 Arena Pharmaceuticals, Inc. DERIVATI SUSPSTITUIRANE 1,2,3,4-TETRAHIDROCIKLOPENTA[b]INDOL-3-IL-OCTENE KISELINE KORISNI U LIJEČENJU AUTOIMUNIH I UPALNIH POREMEĆAJA
CN105816453B (zh) 2008-08-27 2021-03-05 艾尼纳制药公司 用于治疗自身免疫性病症和炎性病症的作为s1p1受体激动剂的经取代的三环酸衍生物
CA2786994C (en) 2010-01-27 2018-01-16 Arena Pharmaceuticals, Inc. Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
TW201130488A (en) * 2010-02-03 2011-09-16 Daiichi Sankyo Co Ltd Pyrrole compound
CN105503882B (zh) 2010-03-03 2019-07-05 艾尼纳制药公司 制备s1p1受体调节剂及其晶体形式的方法
BE1019432A3 (fr) * 2010-07-23 2012-07-03 Auriga Internat Utilisation d'isothiocyanates et derives pour le traitement et/ou la prevention des lucites.
AU2016205361C1 (en) 2015-01-06 2021-04-08 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor
PL3310760T3 (pl) 2015-06-22 2023-03-06 Arena Pharmaceuticals, Inc. Krystaliczna sól L-argininy kwasu (R)-2-(7-(4-cyklopentylo-3-(trifluorometylo)benzyloksy)- 1,2,3,4-tetrahydrocyklo-penta[b]indol-3-ilo)octowego do zastosowania w zaburzeniach związanych z receptorem S1P1
JP2020507610A (ja) 2017-02-16 2020-03-12 アリーナ ファーマシューティカルズ， インコーポレイテッド 腸管外症状を伴う炎症性腸疾患の治療のための化合物および方法
KR20190116416A (ko) 2017-02-16 2019-10-14 아레나 파마슈티칼스, 인크. 원발 담즙성 담관염을 치료하기 위한 화합물 및 방법
AU2019280822A1 (en) 2018-06-06 2021-01-07 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor
EP3847158A1 (en) 2018-09-06 2021-07-14 Arena Pharmaceuticals, Inc. Compounds useful in the treatment of autoimmune and inflammatory disorders
ES3049760T3 (en) 2020-06-08 2025-12-18 Univ Toyama Prefectural Toll-like receptor 7 activation inhibitors for the treatment of autoimmune diseases

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0627406B1 (en) * 1992-10-21 1998-10-28 Yoshitomi Pharmaceutical Industries, Ltd. 2-amino-1,3-propanediol compound and immunosuppressant
JP3870419B2 (ja) * 1994-08-22 2007-01-17 三菱ウェルファーマ株式会社 ベンゼン化合物およびその医薬としての用途
US5948820A (en) * 1994-08-22 1999-09-07 Yoshitomi Pharmaceutical Industries, Ltd. Benzene compound and pharmaceutical use thereof
CA2286315C (en) * 1997-04-04 2007-03-06 Yoshitomi Pharmaceutical Industries Ltd. 2-aminopropane-1,3-diol compound, pharmaceutical use thereof and synthetic intermediates therefor
NZ533997A (en) * 2000-07-13 2005-11-25 Sankyo Co Amino alcohol derivatives
US20030060502A1 (en) * 2001-09-19 2003-03-27 Francois Mach Treatment of diabetes with statins (HMG-COa reductase inhibitors)
ATE463478T1 (de) * 2001-09-27 2010-04-15 Kyorin Seiyaku Kk Diaryletherderivat, dessen additionssalz und immunosuppressivum
AU2002332289B2 (en) * 2001-09-27 2007-05-10 Kyorin Pharmaceutical Co., Ltd. Diaryl sulfide derivative, addition salt thereof, and immunosuppressant
RU2330839C2 (ru) * 2002-01-11 2008-08-10 Санкио Компани, Лимитед Производные аминоспиртов или производные фосфорных кислот и фармацевтические композиции, содержащие указанные производные
AU2003273865A1 (en) * 2002-09-13 2004-04-30 Novartis Ag Amino-propanol derivatives
TWI355934B (en) * 2004-02-24 2012-01-11 Sankyo Co Pharmaceutical composition for treatment or prophy
MXPA06012663A (es) * 2004-05-03 2007-01-16 Novartis Ag Combinaciones que comprenden un agonista del receptor s1p y un inhibidor de quinasa jak3.
ATE502630T1 (de) * 2004-07-16 2011-04-15 Kyorin Seiyaku Kk Verfahren zur effektiven anwendung eines medikaments und verfahren zur prävention von nebenwirkungen
TWI418350B (zh) * 2005-06-24 2013-12-11 Sankyo Co 含有ｐｐａｒ調節劑之醫藥組成物的用途

Also Published As

Publication number Publication date
ATE538780T1 (de) 2012-01-15
EP1782804A1 (en) 2007-05-09
TW200611687A (en) 2006-04-16
ES2377975T3 (es) 2012-04-03
KR20070042986A (ko) 2007-04-24
WO2006011554A1 (ja) 2006-02-02
EP1782804A4 (en) 2010-12-15
CA2575518A1 (en) 2006-02-02
EP1782804B1 (en) 2011-12-28
US20070149597A1 (en) 2007-06-28
CN101027048A (zh) 2007-08-29

Similar Documents

Publication Publication Date Title
EP1782804A4 (en) MEDICAL COMPOSITION AS IMMUNOSUPPRESSIVUM
EP1403235A4 (en) N-ARYLPHENYLACETAMIDE DERIVATIVES AND MEDICAL COMPOSITIONS CONTAINING THEREOF
MX340965B (es) Combinaciones para el tratamiento de enfermedades que involucran la proliferacion celular.
DK1140745T3 (da) Colchinolderivater som vaskulært skadelige midler
NO20071042L (no) 5-substituerte 2-fenylaminobenzamider som MEK-inhibitorer
NO20071137L (no) Nye piperidinderivater for behandling av depresjon
AU2003225617A1 (en) Thiadiazolylpiperazine derivatives useful for treating or preventing pain
DE60206911D1 (de) Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren
BRPI0407616A (pt) composto, composição farmacêutica, método para bloquear uma combinação de receptor de mu, capa, delta (heterodìmero) deste em mamìferos, método para tratar ou prevenir obesidade e doenças relacionadas, uso de um composto, e método de suprimir o apetite em um paciente em necessidade deste"
ATE449083T1 (de) Chinazolin-derivate und ihre verwendung als arzneimittel
WO2007099162A3 (fr) Derive de resveratrol a longue chaine hydroxylee utiles comme neurotrophiques
ATE450499T1 (de) Durch enzyme spaltbare prodrugs von substituierten stickstoff-lost-derivaten
TW200630364A (en) 2-amido-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof
BR0314352A (pt) Indóis 2,7-substituìdos e seu uso como moduladores de 5-ht6
DE602005022764D1 (de) Piperidin- und azetidinderivate als glyt1-inhibitoren
AR043253A1 (es) 4-[(2,4-dicloro-5-metoxifenil)amino] -6- alcoxi-3-quinolina carbonitrilos para el tratamiento de lesiones isquemicas
DE60202682D1 (de) Chinoline derivate und ihre anwendung als antitumor agentien
CA2373395A1 (en) Sulfonyl pyridazinone compounds useful as aldose reductase inhibitors
DE60009517D1 (de) A-500359-derivate
EA200600022A1 (ru) Применение производных бицикло [2.2.1] гептана для приготовления нейропротекторных фармацевтических композиций
CY1113801T1 (el) Παραγωγο κιναζολινης και φαρμακευτικο ειδος
MA28930B1 (fr) Derives pyridiniques d'indolin-2-one , leur preparation et leur application en therapeutique
EA200500716A1 (ru) Новые соединения 2,3-дигидро-4-(1h)-пиридона, способ их получения и фармацевтические композиции, которые их содержат
TW200740428A (en) Substituted propanamide derivatives and pharmaceutical compositions thereof
MXPA05008190A (es) Derivado de oligosacarido.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.